Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia
Joshua R. Huot, Leah J. Novinger, Fabrizio Pin, Ashok Narasimhan, Teresa A. Zimmers, Thomas M. O’Connell, Andrea Bonetto
Joshua R. Huot, Leah J. Novinger, Fabrizio Pin, Ashok Narasimhan, Teresa A. Zimmers, Thomas M. O’Connell, Andrea Bonetto
View: Text | PDF
Research Article Cell biology Muscle biology

Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia

  • Text
  • PDF
Abstract

Advanced colorectal cancer (CRC) is often accompanied by development of liver metastases (LMs) and skeletal muscle wasting (i.e., cachexia). Despite plaguing the majority of CRC patients, cachexia remains unresolved. By using mice injected with Colon-26 mouse tumors, either subcutaneously (s.c.; C26) or intrasplenically to mimic hepatic dissemination of cancer cells (mC26), here we aimed to further characterize functional, molecular, and metabolic effects on skeletal muscle and examine whether LMs exacerbate CRC-induced cachexia. C26-derived LMs were associated with progressive loss of body weight, as well as with significant reductions in skeletal muscle size and strength, in line with reduced phosphorylation of markers of protein anabolism and enhanced protein catabolism. mC26 hosts showed prevalence of fibers with glycolytic metabolism and enhanced lipid accumulation, consistent with abnormalities of mitochondrial homeostasis and energy metabolism. In a comparison with mice bearing s.c. C26, cachexia appeared exacerbated in the mC26 hosts, as also supported by differentially expressed pathways within skeletal muscle. Overall, our model recapitulates the cachectic phenotype of metastatic CRC and reveals that formation of LMs resulting from CRC exacerbate cancer-induced skeletal muscle wasting by promoting differential gene expression signatures.

Authors

Joshua R. Huot, Leah J. Novinger, Fabrizio Pin, Ashok Narasimhan, Teresa A. Zimmers, Thomas M. O’Connell, Andrea Bonetto

×

Figure 11

RNA sequencing analysis of skeletal muscle reveals differentially expressed genes in C26 and mC26 mice.

Options: View larger image (or click on image) Download as PowerPoint
RNA sequencing analysis of skeletal muscle reveals differentially expres...
Next-Generation RNA sequencing was performed on whole RNA extracted from skeletal muscle of CD2F1 male mice (8 weeks old) either injected with C26 tumor cells s.c. (1,000,000 cells/mouse in sterile PBS, C26) or intrasplenically (250,000 cells/mouse in sterile PBS, mC26). Control (Con for C26) and Sham (controls for mC26) were injected with an equal volume of vehicle (n = 5–6). (A) Heatmap representing the full list of differentially expressed genes in both C26 and mC26 skeletal muscle. Cut-offs for genes were fold-change of 1.5 and a FDR of 0.05. (B) Differential expression analysis identified 4277 common genes between C26 and mC26, along with several unique genes. (C) Top 10 representative pathways: Analysis was performed using the unique genes from C26 (1227 genes) and mC26 (1494 genes). Square dots indicate –Log10 P value. Blue indicates the pathways identified in C26, and red indicates the pathways in mC26. (D and E) Upstream regulators identified in our differential expression analysis for C26 and mC26. Blue indicates inhibition, and orange indicates activation of the regulator.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts